Signal #151905 · SEC 8-K

$ELVN SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $ELVN filing catalyst

Why did $ELVN trigger an AI stock catalyst alert?

$ELVN triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.0/10). Headline: Enliven Therapeutics Aligns with FDA on Phase 3 ENABLE-2 Design; Cash Runway to 2030. Key points: - Reached FDA alignment on ENABLE-2 Phase 3 design; trial initiation on track for year-end 2026. - Balance sheet holds $884.4M in cash and equivalents, providing runway into 2030. - Q3 2026 net loss expanded to $27.7M ($0.36/share) vs. $20.1M in Q3 2025 due to higher R&D spend.

How did $ELVN stock react after the SEC filing?

After the SEC 8-K for $ELVN, observed market reaction: T0 price $44.79. Past moves do not guarantee future results.

Where can I get real-time $ELVN SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $ELVN via Telegram and the VIP Web Terminal from €10/month.

$ELVN

$ELVN – Enliven Therapeutics Aligns with FDA on Phase 3 ENABLE-2 Design; Cash Runway to 2030

Enliven Therapeutics, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $ELVN

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.0 / 10)

Reached FDA alignment on ENABLE-2 Phase 3 design; trial initiation on track for year-end 2026.
Balance sheet holds $884.4M in cash and equivalents, providing runway into 2030.
Q3 2026 net loss expanded to $27.7M ($0.36/share) vs. $20.1M in Q3 2025 due to higher R&D spend.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →